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Infection with human papillomaviruses (HPV) is the
major risk factor for the development of cervical cancer.
The HPV E7 oncogene is constitutively expressed in
infected cells hence it represents a promising target for
immune therapy of HPV-related disease. For safety rea-
sons the use of a transforming gene for DNA vaccination
is not feasible. Therefore, we have generated a rearranged
('shuffled') HPV16 E7 artificial gene (HPV16 E7SH) spe-
cifically dissected at the sites associated with cell transfor-
mation. Sequence duplications were added in order to
supply all original T cell epitopes. The potential risk of
back to wild type recombination was reduced by the use
of different codons in the duplicated sequences.
Our objective was to investigate whether the HPV16 E7SH
gene is lacking detectable transforming properties and
shows E7-specific tumor rejection in mice and immuno-
genicity in humans. The E7SH genes were generated by
fusion-PCR using overlapping primers. For DNA immuni-
zation, the genes were cloned into vector pTHamp (kindly
provided by T. Hanke, Oxford, UK) and injected intra-
muscularly (i.m.) into female C57BL/6 mice. CD8+ T cell
responses were measured by ELISPOT and 51Cr-release
assays. Tumor regression experiments in immunized mice
were performed after inoculation of HPV16 E7 wild type-
expressing syngeneic C3 cells. Soft-agar transformation
assays were performed to compare transforming capacity
of wild type and artificial E7SH genes in murine cells.
E7SH recombinant retroviral vectors were generated for
infection of NIH3T3. Human monocyte-derived dendritic
cells were transfected by nucleoporation and HPV16
E7SH expression was investigated by RT-PCR, Western
blot, and specific T cell stimulation in vitro.
Intramuscular immunization with the pTHamp-E7SH
expression plasmid induced E7-specific cytotoxic T cell
responses as detected ex vivo by IFN-γ ELISPOT and after
in vitro restimulation by 51Cr-release assays. Two i.m.
immunizations with pTHamp-E7SH were sufficient to
mediate regression of established C3 tumors in C57BL/6
mice. The E7SH gene has lost its transforming properties
as analyzed by in vitro soft-agar-transformation assays.
After transfection of immature and mature human mono-
cyte-derived dendritic cells recombinant HPV16 E7SH
expression was detected by RT-PCR, Western blot analysis,
and in vitro stimulation of autologous E7-specific T cells
suggesting potential immunogenicity in humans. Our
data indicate that the HPV16 E7SH gene efficiently
induces cytotoxic T cells directed against the wild type E7
antigen as measured in vitro and in vivo. The construct will
be tested in clinical phase I trials to proof safety and
immunogenicity in patients.
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